

Epinex G1A™ Test Featured in *Medical Device Daily*

The Epinex G1A™ test was the subject of the lead article in the October 31st, 2006 edition of *Medical Device Daily*, the subscription newspaper of record for the high-tech medical technology industry. *MDD* is relied on by thousands of industry insiders every business morning.

Prominent Diabetes Blog Advocates G1A™ Test

**TheDiabetesBlog.com receives
over 300,000 unique hits per day
Bridging The Gap To Reduce
Diabetic Complications**

Allie Beatty
Oct. 20, 2006

The hemoglobin A1c has been regarded as the undisputed champion for measurement of glycemic control...until now. Those of us running from diabetic complications understand the necessity of this test. Waiting 3 months (or more) gives these glycated red blood cells a lot of time to play havoc with our small blood vessels, over time resulting in a quagmire of diabetic complications. Glycation is the cause of the long-term complications of diabetes. There is a gap between the data provided by daily blood glucose testing and the information on the long-term health of the diabetic patient supplied by the HbA1c test.

Epinex Diagnostics developed the G1A to measure the albumin in the blood, not the hemoglobin...in contrast to daily blood glucose and semi-annual A1c testing, the G1A glycated albumin index offers a more accurate predictor of glycation by testing once a month, instead of testing the A1c every 3 or 6 months.

I'm not sure about you, but if someone said they know of a way to manage my diabetes that is more effective, less time consuming, and allows for earlier therapeutic intervention-- *sign me up!* The G1A has the potential to become the new industry standard for diabetes management. Ask your doctor if he or she has heard of it yet.

MEDICAL DEVICE DAILY™

THE DAILY MEDICAL TECHNOLOGY NEWSPAPER

TUESDAY, OCTOBER 31, 2006

VOL. 10, No. 209

PAGE 1 OF 9

Epinex develops prototype for monthly Type 2 diabetes test

By **KAREN YOUNG**
Medical Device Daily Staff Writer

Development-stage company **EpineX Diagnostics** (Irvine, California) said it has completed the development of a proof-of-concept prototype for a monthly rapid test to monitor Type 2 diabetes.

The company said such a test might provide information sooner to diabetics about whether or not they are doing a good job of managing their blood glucose levels by providing a measurement of glycated albumin, compared to total albumin in a person's bloodstream. It says that albumin is the most abundant protein in the bloodstream and is subject to damage by excess levels of sugar in the blood.

"[Our test] measures serum protein glycation, specifically glycated albumin, and compares it to total serum albumin; that's how it gives an index as a percentage," David Trasoff, PhD, director of communications at EpineX, told *Medical Device*

• The full text of the article is available on the EpineX web site •

EPINEX ISSUES PRESS RELEASE FOR G1A™ TEST

On October 23rd, 2006 EpineX issued a press release through Biomedical Market News to a database of 250,000 email addresses in the biomedical market space. The release, *New Monthly Rapid Test To Monitor Diabetes Developed*, generated over 120,000 hits to the EpineX web site. Our information was viewed by government agencies, health care institutions, universities and major pharmaceutical and medical device companies, including: Agilent, BristolMeyerSquibb, Siemens, Roche, the US Dept. of Health & Human Services, the American Society of Health System Pharmacists, Cincinnati Children's Hospital, St. Jude Hospital, John Muir Health Hospital, Vancouver General Hospital-Canada, Robert Koch Institute-Germany, Children's Hospital of Philadelphia, London Health Science Center-Canada, and the University of Pittsburgh Medical Center.

Corporate Office:

EpineX Diagnostics, Inc.
2815 McGaw Avenue
Irvine, California 92614 USA
www.epinex.com

Corporate Finance:

Jeff Byrd, Vice President
Toll Free: (866) 592-3746
jeff@epinex.com



EPINEX DIAGNOSTICS INC.

CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS

